MME and hydrops fetalis: In the PARADIGM-HF trial, the combination of the neprilysin inhibitor sacubitril with the angiotensin receptor antagonist valsartan demonstrated a significant reduction in the occurrence of the composite endpoint, which consisted of death, death from cardiovascular cause, and the need for hospitalization for heart failure (HF), when compared to the treatment with enalapril alone (6).